Table 2.
Univariate analysis of predictive factors for ATO-induced hepatotoxicity
| Clinical characteristics | All Patients (N = 122) | ||
|---|---|---|---|
| Cases | Controls | ||
| Hepatotoxicity, no. (%) | Nonhepatotoxicity, no. (%) | P | |
| Total | 112 (91.80%) | 10 (8.20%) | — |
| Age, years | |||
| > 50 | 36 (92.31%) | 3 (7.69%) | 0.889a |
| ≤ 50 | 76 (91.57%) | 7 (8.43%) | |
| Sex | |||
| Female | 53 (92.98%) | 4 (7.02%) | 0.749a |
| Male | 59 (90.77%) | 6 (9.23%) | |
| WBC count, × 109/L | |||
| ≤ 10 | 90 (92.78%) | 7 (7.22%) | 0.426a |
| > 10 | 22 (88%) | 3 (12%) | |
| Platelet count, × 109/L | |||
| ≥ 30 | 44 (89.80%) | 5 (10.20%) | 0.508 |
| < 30 | 68 (93.15%) | 5 (6.85%) | |
| Hemoglobin level, g/L | |||
| ≥ 80 | 58(95.08%) | 3 (4.92%) | 0.323a |
| < 80 | 54 (88.52%) | 7 (11.48%) | |
| Fibrinogen level, g/L | |||
| ≥ 1 | 75 (93.75%) | 5 (6.25%) | 0.279 |
| < 1 | 37 (88.10%) | 5 (11.90%) | |
| Prophylactic hepatoprotective agents | |||
| Yes | 22 (78.57%) | 6 (21.43%) | 0.01**a |
| No | 90 (95.74%) | 4 (4.26%) | |
| Anti-leukocytosis agents | |||
| Single ATO | 68 (89.47%) | 8 (10.53%) | 0.317a |
| ATO + chemotherapy | 44 (95.65%) | 2 (4.35%) | |
Bold values and * are statistically significant (P < 0.05); Bold values and * are statistically significant (P < 0.01); ATO, arsenic trioxide; a, P-values for categorical variables are from Fisher’s exact test (n < 5)